Clinical Trial Update: Efficacy of Indacaterol 150 µg Versus Formoterol [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing indacaterol 150 µg versus formoterol for chronic obstructive pulmonary disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol (formoterol)
• Indacaterol (indacaterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: WITHDRAWN